Beneficial use of Cetaphil® Moisturizing Cream as part of a daily skin care regimen for individuals with rosacea

Journal of Dermatological Treatment

Volumn 18, Issue 3, 2007, Pages 158-162

  Laquieze, Sabine ^a   Czernielewski, Janusz ^b   Baltas, Eszter ^b  

^a PERITESCO   (France)

^b Galderma R and D   (France)

Author keywords

Moisturizer; Rosacea; Sensitive skin; Skin barrier

Indexed keywords

CETAPHIL; DERMATOLOGICAL AGENT; METRONIDAZOLE; ROZEX; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; DIAGNOSTIC AGENT; DODECYL SULFATE SODIUM; FATTY ALCOHOL; LACTIC ACID; PROPANEDIOL DERIVATIVE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DESQUAMATION; DRY SKIN; ELECTRIC CAPACITANCE; FEMALE; HUMAN; MALE; MEASUREMENT; MEDICAL ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ROSACEA; SKIN CARE; SKIN SENSITIVITY; WATER LOSS; ADOLESCENT; AGED; DRUG ADMINISTRATION; DRUG COMBINATION; GEL; HOSPITALIZATION; INTRADERMAL DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY; THERMOREGULATION; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AGED; ANTI-INFECTIVE AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; ELECTRIC CAPACITANCE; FATTY ALCOHOLS; FEMALE; GELS; HUMANS; LACTIC ACID; MALE; METRONIDAZOLE; MIDDLE AGED; PROPYLENE GLYCOLS; ROSACEA; SEVERITY OF ILLNESS INDEX; SKIN CARE; SODIUM DODECYL SULFATE; TREATMENT OUTCOME; WATER LOSS, INSENSIBLE;

EID: 34249800367     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630601121078     Document Type: Article

References (18)

1. Gupta AK, Chaudhry MM. Rosacea and its management: an overview. J Eur Acad Dermatol Venereol. 2005;19:273-85.
2. Crawford GH, Pelle MT, James WD. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol. 2004;51:327-41; quiz 342-4.
3. Powell FC. Clinical practice. Rosacea. N Engl J Med. 2005;352:793-803.
4. Wilkin J, Dahl M, Detmar M, Drake L, Liang MH, Odom R, et al. National Rosacea Society Expert Committee. Standard grading system for rosacea: Report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol. 2004;50:907-12.
5. Nally JB, Berson DS. Topical therapies for rosacea. J Drugs Dermatol. 2006;5:23-6.
6. Draelos ZD. Cosmetics in acne and rosacea. Semin Cutan Med Surg. 2001;20:209-14.
7. Draelos ZD. Facial hygiene and comprehensive management of rosacea. Cutis. 2004;73:183-7.
8. Pelle MT, Crawford GH, James WD. Rosacea: II. Therapy. J Am Acad Dermatol. 2004;51:499-512; quiz 513-14.
9. Zip C. An update on the role of topical metronidazole in rosacea. Skin Therapy Lett. 2006;11:1-4.
10. Dahl MV, Katz HI, Krueger GG, Millikan LE, Odom RB, Parker F, et al. Topical metronidazole maintains remissions of rosacea. Arch Dermatol. 1998;134:679-83.
11. Del-Rosso JQ. Cutaneous tolerability of metronidazole topical gel 0.75% for rosacea. Cosmet Dermatol. 2005;18:559-62.
12. Ziel K, Yelverton CB, Balkrishnan R, Feldman SR. Cumulative irritation potential of metronidazole gel compared to azelaic acid gel after repeated applications to healthy skin. J Drugs Dermatol. 2005;4:727-31.
13. Del-Rosso JQ. Understanding skin cleansers and moisturizers: The correlation of formulation science with the art of clinical use. Cosmet Dermatol. 2003;16:19-31.
14. Kraft JN, Lynde CW. Moisturizers: What they are and a practical approach to product selection. Skin Therapy Lett. 2005;10(5):1-8.
15. Rim JH, Jo SJ, Park JY, Park BD, Youn JI. Electrical measurement of moisturizing effect on skin hydration and barrier function in psoriasis patients. Clin Exp Dermatol. 2005;30:409-13.
16. Lonne-Rahm SB, Fischer T, Berg M. Stinging and rosacea. Acta Derm Venereol. 1999;79:460-1.
17. Jappe U, Schnuch A, Uter W. Rosacea and contact allergy to cosmetics and topical medicaments - retrospective analysis of multicentre surveillance data 1995-2002. Contact Dermatitis. 2005;52:96-101.
18. Del Rosso JQ. Adjunctive skin care in the management of rosacea: Cleansers, moisturizers, and photoprotectants. Cutis. 2005;75(3 Suppl):17-21; discussion 33-6.